Compare SOPH & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOPH | EIC |
|---|---|---|
| Founded | 2011 | N/A |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.7M | 233.7M |
| IPO Year | 2021 | N/A |
| Metric | SOPH | EIC |
|---|---|---|
| Price | $5.05 | $9.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.00 | ★ $12.63 |
| AVG Volume (30 Days) | 96.2K | ★ 165.8K |
| Earning Date | 03-03-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 13.82% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.16 | $0.37 |
| Revenue Next Year | $17.56 | $1.08 |
| P/E Ratio | ★ N/A | $9.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.58 | $9.33 |
| 52 Week High | $5.70 | $15.20 |
| Indicator | SOPH | EIC |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 28.73 |
| Support Level | $4.54 | N/A |
| Resistance Level | $5.30 | $10.15 |
| Average True Range (ATR) | 0.26 | 0.18 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 67.24 | 11.59 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.